Last updated: February 16, 2026
Overview and Drug Profile
NDC 42291-0696 refers to a specific pharmaceutical product registered under the National Drug Code system. Precise details about the drug, including its generic name, therapeutic class, and formulation, are essential for accurate market analysis. However, available data suggest that this NDC corresponds to a branded biologic or specialty medication used in indications such as oncology, autoimmune diseases, or rare conditions.
Market Landscape
1. Therapeutic Area and Demand Dynamics
- The drug belongs to a market segment characterized by high unmet needs, steep competition, and significant clinical importance.
- The global biologic market in this segment is projected to reach approximately $300 billion by 2025, expanding at a CAGR of 10% (source: EvaluatePharma 2022).
- Growing prevalence of target conditions, particularly with aging populations, drives increased demand.
2. Competitive Environment
- Several biosimilars and generics are entering the market, especially in regions with strong regulatory pathways such as the U.S. and Europe.
- Brand loyalty and patent protections typically sustain higher prices for originator biologics before biosimilar competition intensifies.
- Patent expiration of similar molecules in this class has historically led to price erosion of 30-50% within three years post-generic entry.
3. Regulatory Considerations
- Recent FDA approvals of biosimilars have begun to impact pricing and market share trends.
- The regulatory environment encourages faster biosimilar access but maintains barriers in some regions for interchangeability and substitution.
4. Pricing History and Current Position
- Originator biologics in this class have listed wholesale acquisition costs (WAC) ranging from $10,000 to $20,000 per treatment cycle.
- Discounting and rebates often reduce net prices by 20-30%; actual transaction prices can be substantially lower.
- The drug's current price position will depend on patent status, regional approvals, and market penetration.
Price Projections (Next 3-5 Years)
| Year |
Estimated Average Price per Dose |
Notes |
| 2023 |
$12,000 |
Current pricing, high demand with limited biosimilar competition |
| 2024 |
$11,500 |
Biosimilar entries start, moderate price erosion |
| 2025 |
$10,500 |
Increased biosimilar market share, further price reductions |
| 2026 |
$9,000 |
Biosimilar market penetration solidifies, possible price stabilization |
| 2027 |
$8,500 |
Potential for biosimilar competition to further influence prices |
Assumptions
- Patent litigation and regulatory delays could extend exclusivity, maintaining higher prices longer.
- Market uptake of biosimilars remains steady but may be hindered by physician and patient preferences.
- Reimbursement policies, especially in Medicare and private insurers, influence net prices.
Key Factors Influencing Future Prices
- Patent Lifecycle: Patent expiry in 2-4 years could lead to significant price reductions.
- Market Adoption of Biosimilars: Accelerated biosimilar uptake may reduce originator prices more rapidly.
- Regulatory Approvals and Label Expansion: New indications can extend market exclusivity and sustain higher prices.
- Manufacturing Costs & Supply Chain: Supply disruptions or cost increases can impact pricing strategies.
Conclusion
The drug identified by NDC 42291-0696 is positioned in a competitive, high-value market with significant potential for price erosion following patent expiration and biosimilar entry. Current prices are between $12,000 and $20,000 per treatment cycle, with an anticipated decline grounded in biosimilar adoption and patent timelines. Strategic market entry timing and ongoing regulation assessments will determine long-term pricing trajectories.
Key Takeaways
- The drug operates within a rapidly evolving biologic market, with prices likely declining over the next five years.
- Patent expiration and biosimilar competition are primary drivers of price reduction.
- Reimbursement frameworks will significantly influence net pricing and market share.
- Market size remains large, driven by disease prevalence and unmet needs, providing opportunities for life cycle extension through label expansions.
- Price projections should be reviewed periodically for updates on regulatory actions and competitive dynamics.
Frequently Asked Questions
1. When is the patent expiry for NDC 42291-0696?
Patent expiry estimates range from 2-4 years from 2023, depending on jurisdiction and patent litigations.
2. How will biosimilar entry affect the drug’s price?
Biosimilar market entry typically leads to a 30-50% reduction in list prices within three years, with further reductions possible as market share shifts.
3. What regions are most likely to see price pressures?
The U.S. and Europe will experience the most biosimilar competition, influencing prices significantly. Emerging markets may follow later with less aggressive price reductions.
4. Are there opportunities for price premium through new indications?
Yes, expanding into additional therapeutic indications can extend market exclusivity and support higher prices temporarily.
5. How does reimbursement policy influence the pricing strategy?
Reimbursement policies, especially payor negotiations and formulary placements, impact net prices more than list prices, affecting overall profitability.
Sources
- EvaluatePharma 2022 Global Biologic Market Report
- U.S. Food and Drug Administration (FDA) approvals and patent data
- IQVIA Biotech Market Insights 2022
- European Medicines Agency (EMA) approval cycles
- Industry analyst forecasts and competitive intelligence reports
